Pembrolizumab In Central Nervous System Metastases
2期
进行中（已停止招募）
NCT02886585
| 适应症 | Brain Metastases |
|---|
| 分期 | 2期 |
|---|
| 申办方 | Massachusetts General Hospital |
|---|
| 状态 | 进行中（已停止招募） |
|---|
| 受试者人数 | 101 人 |
|---|
| 干预（药物） | Pembrolizumab, MRI, PET/CT, Stereotactic Radiosurgery |
|---|
| 开始日期 | 2016年10月 |
|---|
| 完成日期 | 2027年6月 |
|---|
| 结果公布日 | 2026年6月26日 |
|---|
摘要
This research study is studying Pembrolizumab as a possible treatment for this diagnosis for metastases in the central nervous system (brain and spinal cord).
Intracranial Benefit Rate (Cohorts A and B)
44 months · percentage of patients
| Previously Untreated Brain Metastases-Cohort A | 33.3 percentage of patients |
|---|
| Progressive Brain Metastases-Cohort B | 43.8 percentage of patients |
|---|
Overall Survival at Three Months (Cohort C)
3 Months · proportion of patients
| Neoplastic Meningitis-Cohort C | 0.60 proportion of patients |
|---|
Extracranial Overall Response Rate (Cohort D)
Data collection is ongoing for this objective. The longest time a single patient has been followed for this measure is 6 years.
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。